(Q36909904)

English

Randomized Phase II Study of Docetaxel plus Personalized Peptide Vaccination versus Docetaxel plus Placebo for Patients with Previously Treated Advanced Wild Type EGFR Non-Small-Cell Lung Cancer

scientific article published on 4 May 2016

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Randomized Phase II Study of Docetaxel plus Personalized Peptide Vaccination versus Docetaxel plus Placebo for Patients with Previously Treated Advanced Wild Type EGFR Non-Small-Cell Lung Cancer (English)

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Koichi Takayama

1

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Shunichi Sugawara

2

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Yasuo Saijo

3

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Makoto Maemondo

4

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Atsushi Sato

5

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Shinzo Takamori

6

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Taishi Harada

7

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Tetsuro Sasada

8

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Tatsuyuki Kakuma

9

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Junji Kishimoto

10

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Akira Yamada

11

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Masanori Noguchi

12

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Kyogo Itoh

13

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Yoichi Nakanishi

14

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

publication date

4 May 2016

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Journal of Immunology Research

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

2016

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

1745108

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

copyright license

Creative Commons Attribution 4.0 International

1 January 2016

1 reference

April 2022 Public Data File from Crossref

copyright status

1 reference

April 2022 Public Data File from Crossref

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4870343

29 September 2017

New strategies in lung cancer: translating immunotherapy into clinical practice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4870343

29 September 2017

Personalized peptide vaccination: a novel immunotherapeutic approach for advanced cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4870343

29 September 2017

Novel cancer immunotherapy agents with survival benefit: recent successes and next steps

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4870343

29 September 2017

Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4870343

29 September 2017

Personalized peptide vaccines: a new therapeutic modality for cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4870343

29 September 2017

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4870343

29 September 2017

Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4870343

27 June 2018

Personalized peptide vaccination in patients with refractory non-small cell lung cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4870343

4 September 2018

A phase II study of personalized peptide vaccination combined with gemcitabine for non-resectable pancreatic cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4870343

4 September 2018

A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4870343

4 September 2018

Immunological evaluation of personalized peptide vaccination in combination with UFT and UZEL for metastatic colorectal carcinoma patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4870343

4 September 2018

Phase III trial of docetaxel plus gemcitabine versus docetaxel in second-line treatment for non-small-cell lung cancer: results of a Japan Clinical Oncology Group trial (JCOG0104).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4870343

4 September 2018

Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4870343

4 September 2018

New multiplexed flow cytometric assay to measure anti-peptide antibody: a novel tool for monitoring immune responses to peptides used for immunization

1 reference

https://pubmed.ncbi.nlm.nih.gov/27274999

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1155/2016/1745108

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

release_sqwul5tp6zbippdojc5jfcfsye

1 reference

https://api.fatcat.wiki/v0/release/sqwul5tp6zbippdojc5jfcfsye

24 November 2022

based on heuristic

mapped directly with Wikidata item

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36909904&oldid=2088572862"